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ABSTRACT
Introduction: Immunisation coverage data in low-
income and middle-income countries (LMICs)
suggest that more strategies need to be
implemented to achieve and sustain optimal vaccine
uptake. Among possible strategies to improve
immunisation coverage are supplementary
immunisation activities (SIAs). We are therefore
interested in conducting a systematic review to
assess whether SIAs complement routine
immunisation programmes to improve vaccination
coverage and prevent disease outbreaks.
Methods: Our systematic review will focus on
studies conducted in LMICs. With the help of an
information specialist, we will search for eligible
studies in PubMed, Web of Science, Scopus, Africa-
Wide, Cochrane Library, WHOLIS, CINAHL, PDQ-
Evidence as well as reference lists of relevant
publications. Additionally, we will contact relevant
organisations such as WHO and GAVI. Two authors
will independently extract data from eligible studies
and independently assess risk of bias by assessing
the adequacy of study characteristics. The primary
meta-analysis will use random effects models due to
expected interstudies heterogeneity. Dichotomous
data will be analysed using relative risk and
continuous data using weighted mean differences
(or standardised mean differences), both with
95% CIs.
Discussion: The findings from this systematic
review will be discussed in the context of
strengthening routine childhood immunisation
services, routine adolescent immunisation services
and introduction of future vaccines against
tuberculosis and HIV/AIDS.
Study strengths: Unbiased selection of many
studies conducted in different settings. This will
strengthen the validity of the review results.
Study limitations: Heterogeneity of the study
settings of the low-income, lower-middle-income
and upper-middle-income countries as well as
heterogeneity in study designs.
BACKGROUND
Infectious diseases are prevalent in low-
income and middle-income countries
(LMICs). For example, tuberculosis (TB) is a
pandemic of great public health concern. In
2011, the WHO estimated that 1.4 million
people died worldwide from TB.1 To control
the TB pandemic, stakeholders have pro-
posed multipronged approaches, including
development of new and more effective vac-
cines, novel and better drug regimens, faster
and more accurate diagnostic tools as well as
strengthening of public health systems.
Among these approaches, more effective TB
vaccines are likely to have the greatest
impact.2 Research and development of new
and better TB vaccines has been accelerated.
There were 12 candidates with new TB vac-
cines in human clinical trials in the year
2012.3 4 For the effective TB vaccines to
achieve the desired impact, vaccination
coverage must be optimal.
Uptake of vaccines delivered through
routine immunisation programmes remains
variable, and often poor in many LMICs,5 6
suggesting that routine immunisation ser-
vices alone are insufﬁcient to achieve
optimal immunisation coverage in LMICs.
Taking into account that TB burden is
highest in LMICs,7 it is likely that future
effective TB vaccines will not reach desirable
vaccination coverage in these settings if deliv-
ered only through the routine immunisation
services. Therefore, additional strategies will
need to be adopted to improve immunisa-
tion coverage, including supplementary
immunisation activities (SIAs).8 9
SIAs have been successfully used in differ-
ent disease conditions, including typhoid,
measles,10–12 polio,13 human papillomavirus14
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and cholera.15 The major reported beneﬁts of SIAs are
increased immunisation coverage, reduced disease
spread and cost effectiveness.16 Abu-Raddad et al2 have
used a mathematical model to show a signiﬁcant additive
public health beneﬁt in the reduction of TB incidence by
incorporating SIAs to other key interventions of neonatal
vaccination and better TB treatment and diagnostic tools.
However, the use of SIAs to improve immunisation
coverage and prevent disease outbreaks in LMICs rela-
tive to routine immunisation services remains controver-
sial.8 17 To utilise SIAs successfully in the control of TB
with future effective vaccines, it is worthwhile to synthe-
sise the current best evidence on the effectiveness of this
strategy. A study conducted in South Africa, a
middle-income country with a high burden of TB,
showed that TB incidence peaks in adolescence and that
adolescents are the greatest force of Mycobacterium tuber-
culosis infection within a population.18 This study sug-
gests that a new effective TB vaccine would have the
greatest impact in the control of TB when targeted at
the adolescent population. We propose to conduct a sys-
tematic review to assess whether, at present, there exists
evidence that SIAs improve immunisation coverage and
reduce disease burden in LMICs.
To the best of our knowledge, the most recent com-
prehensive systematic review on SIAs was conducted by
Dietz and Cutts16 in 1997 and involved studies published
up to 1992. Since then, there have been many changes,
among them population increase,19 change in disease
epidemiology,20 emergence of antivaccine groups21 as
well as expanded healthcare infrastructure. These
changes may negatively affect the performance of
immunisation services in obtaining optimal vaccination
coverage. Furthermore, new vaccines continue to be
incorporated in the existing Expanded Programme on
Immunisation,22 23 adding more logistical and ﬁnancial
pressure to the routine immunisation services.
In the context of these changes that may affect the
vaccination coverage, it is rational to hypothesise that at
present the effects of SIAs in complementing routine
immunisation services may be different from those
reported in the past by Dietz and Cutts in 1997. In
support of this hypothesis, some authors reported that
SIAs negatively affect the routine immunisation ser-
vices,24 25 whereas some studies report the opposite:
SIAs increase immunisation coverage and reduce disease
outbreaks.26–29 Therefore, an up to date systematic
review is critical to provide evidence on the relevance of
SIAs in the current health systems environment. This evi-
dence will be useful, particularly for LMICs, because
these settings are the epicentre of vaccine-preventable
diseases and (by deﬁnition) have limited resources.
OBJECTIVES
1. To determine whether SIAs increase vaccination
coverage and reduce disease outbreaks in LMICs.
2. To describe the lessons learnt during SIAs and how
these may guide the introduction of future vaccines
(TB, HIV, malaria) in LMICs.
METHODS
Types of studies
We will consider primary studies with the following
designs:
▸ Intervention studies: individually randomised con-
trolled trials (RCTs), cluster-RCTs, non-RCTs, inter-
rupted time series and controlled before-and-after
studies.
▸ Observational studies: cohort studies, case–control
studies and cross-sectional studies.
Review articles will be excluded.
Study settings
Studies conducted in LMICs as deﬁned by the World
Bank gross domestic product ranking in July 2013.
Types of interventions
This study will focus on SIAs, also referred to as mass
vaccination campaigns. SIAs are deﬁned as immunisa-
tion activities whereby a vaccine is taken simultaneously
to many residents of a community within a deﬁned
short space of time. We will exclude studies of routine
immunisation services, that is, immunisation services
rendered (at ﬁxed, outreach or mobile sites) regularly
throughout the year. In addition, mass campaigns con-
ducted for purposes other than immunisation, for
example, mass information campaigns to educate com-
munities about general health issues will not be
included.
Types of outcome measures
Primary outcomes
▸ Vaccination coverage achieved during SIAs
▸ Disease outbreaks
▸ Disease incidence
Secondary outcome
▸ Immunisation coverage
Search methods for identification of studies
A comprehensive search strategy will be developed,
including various terms relating to SIAs and LIMCs, for
identiﬁcation of published and unpublished articles with
no language restriction. We will search academic peer-
reviewed journals, grey literature (non-published or non-
reviewed papers, reports) and reference lists of relevant
publications. The detailed electronic search strategy is
provided in online supplementary appendix 1 while the
summary of the search outputs retrieved from different
databases is in online supplementary appendix 2.
Electronic searches
We will search the following electronic databases for
primary studies: PubMed, Web of Science, Cochrane
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Central Register of Controlled trials (CENTRAL),
Scopus, Africa Wide, PDQ-Evidence, WHOLIS and
CINAHL.
Data collection and analysis
Selection of studies
Two authors will independently screen the search
outputs for potentially eligible studies, compare their
results and resolve disagreements by discussion and con-
sensus. The two authors will then independently go
through the full text of all potentially eligible studies to
assess whether the studies meet the inclusion criteria
deﬁned by the study design, setting, intervention and
outcomes. Discrepancies in the list of eligible studies
between the two authors will be resolved through discus-
sion and consensus.
Data extraction
A structured and standardised data collection form has
been developed for extracting data from the selected
studies. The form will capture key study characteristics,
including methods, participants and outcomes (see
online supplementary appendix 3). Prior to use, the
extraction form will be piloted on at least four included
studies identiﬁed randomly from the list of included
studies.
Assessment of risk of bias in included studies
The quality of studies will be assessed using the
Cochrane Collaboration’s tool for assessing risk of bias30
for experimental studies and the Scottish Intercollegiate
Guidelines Network (SIGN) checklist for other study
designs.31
Measures of treatment effect
We will express the result of each study as a risk ratio
with its corresponding 95% CIs for dichotomous data,
or mean difference with its SD for continuous data. We
will conduct a meta-analysis for the same type of partici-
pants, interventions, study designs and outcome mea-
sures where homogeneity of data allows. Heterogeneity
will be assessed using the χ² test of homogeneity, and
quantiﬁed using the I2 statistic.32 33
Dealing with missing data
The data will be analysed on an intention-to-treat basis
as far as possible and attempts will be made to obtain
missing data from the original corresponding author.
Where missing data are unobtainable, imputation of
individual values will be undertaken for the primary out-
comes only. For other outcomes, only the available data
will be analysed. Any imputation undertaken will be sub-
jected to sensitivity analysis. If studies report sufﬁcient
detail to calculate mean differences but no information
on associated SD, the outcome will be assumed to have
SD equal to the highest SD from other studies within
the same analysis.
Data synthesis
All eligible studies will be summarised and analysed
using Stata V.12 for Windows. Two authors will extract
the data; the ﬁrst author will enter all data and the
second author will recheck all entries. Disagreements
will be resolved by discussion. If the studies are sufﬁ-
ciently similar, we will combine the data using the
random effects model due to the anticipated heterogen-
eity that may result from the difference in methodology
and study settings. Where the rating scales used in the
studies have a reasonably large number of categories
(more than 10), the data will be treated as continuous
variables arising from a normal distribution. We will use
the weighted mean difference when the pooled studies
use the same rating scale or test, and the standardised
mean difference, the absolute mean difference divided
by the SD, when the studies use different rating scales or
tests. When the rating scales used are fewer than 10 and
more than 2, we will concatenate the data into two cat-
egories that best represent the contrasting states of inter-
est, and treat the outcome measure as binary. Study
results for dichotomous data will be expressed as relative
risk and 95% CI. Time-to-event outcomes or generic
inverse variance outcomes, such as survival time
and time to cure, will be expressed as the log HR and
95% CI.
When studies cannot be combined for meta-analysis
due to diversity of interventions, narrative syntheses will
be conducted and results of individual studies will be
displayed graphically to enable a more succinct
summary of evidence.
Unit of analysis
All cluster randomised trials that meet the inclusion cri-
teria will be included in the meta-analysis after adjusting
for design effect using the variation inﬂation
method:34 35 design effect=1+(M−1) ICC, where M is
the average cluster size and ICC is the intracluster correl-
ation coefﬁcient. If the authors did not report the ICC,
we will use ICC from a similar published trial. For esti-
mated values of ICC, we will conduct sensitivity analyses
using larger and smaller ICCs to determine if the results
are robust.
Assessment of heterogeneity
We anticipate substantial variation in study results due to
differences in the study design, cointerventions, study
settings (low-income vs lower-middle-income vs upper-
middle-income countries) and risk of bias. We will
examine statistical heterogeneity between study results
using the χ² test of homogeneity (with signiﬁcance
deﬁned at the α-level of 10%), and quantify any statis-
tical heterogeneity between study results using the
I2 statistic.30
Assessment of reporting biases
A funnel plot will be used to investigate the risk of publi-
cation bias by intervention type, provided 10 or more
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studies are included in the analysis for each intervention
type.36 37 The funnel plot will be critically examined for
asymmetry.
Sensitivity analysis
We will conduct sensitivity analysis to establish if the
meta-analysis results are inﬂuenced by: the effect of
study designs; publication type (peer-reviewed vs grey lit-
erature); the geographical settings (low-income vs lower-
middle-income vs upper-middle-income countries); and
study period (published before 2000 vs published after
2000).
DISCUSSION
This systematic review will establish whether SIAs
improve immunisation coverage, prevent disease out-
breaks and have a negative impact on routine immunisa-
tion services in LMICs. The review will provide an
up-to-date evidence base of the beneﬁts and harms of
the use of SIAs in the control of vaccine-preventable
disease. Additionally, we will discuss how the ﬁndings of
this review may be applicable in the context of future
vaccines against TB, HIV and malaria.
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